• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Intra-Cellular

Quote
anonymous said:
I had an opportunity to throw my hat in the ring for one of these openings, but I ultimately decided to sit this one out. Coming to market with only a schizophrenia indication relegates much of your selling to community mental health clinics, as mentioned above. A novel mechanism will certainly raise some eyebrows but the majority of the end users are not being treated in a private practice setting and are a heavily subsidized patient population. In my state, all of the managed medicaid plans require a minimum of two generic atypicals before they will even consider covering a branded agent with a prior auth. In that regard, Caplyta will just be the next branded agent on the non-preferred list. An additional indication for bipolar is the game-changer. Unless you are going to sell this product with a wink and a nod to private psychs under the umbrella of “class effect” efficacy in bipolar folks....it’s going to be a bit of a slog in the early stages of launch. Best wishes to you anyway.
Click to expand...

I pulled out of the 2nd round interview myself. After everything I read on cafe pharma and just selling another me too Schizophrenia drug, it just didnt make sense for me to leave a company that I love with no issues. I just didnt feel right about the opportunity. Good luck to those who are hired!
 




anonymous said:
I pulled out of the 2nd round interview myself. After everything I read on cafe pharma and just selling another me too Schizophrenia drug, it just didnt make sense for me to leave a company that I love with no issues. I just didnt feel right about the opportunity. Good luck to those who are hired!
Click to expand...

AGREED !!! GOOD LUCK TO ALL. KEEEP YOUR RESUMES UPDATED
 








anonymous said:
It’s pretty obvious the managers had their “own people” they wanted to bring over. Even reps with very little to no psychiatry experience. It’s basically old Forest labs made up all over again - good old boy network. Just watch- b&c target payout will be low, tons of sample dropping and hard AF managed care coverage with plenty of metric check the boxes...

as for clinical data, it didn’t look that great. Look at it online if you don’t believe me. I believe it will do ok but by no means a blockbuster The efficacy was decent but again not a home run where providers are going to jump on it. It’ll be the train wreck patient who isn’t compliant and it’ll stay around a 1% market share- then in say 3-5 years the company will have a hostile take over or ceo will sell.
And anyone working for dragon I mean degan, better get on his board of micro managing or hope off the train
Click to expand...

This is very common with Psy drug launches. the DM brings a lot of their people REGARDLESS OF ABILITY. Good luck to all,
 








anonymous said:
Really? This week? Interesting.

When do they expect to announce the next round of clinical trial data on the additional indications to be released?

Anyone still in round 2 of hiring heard anything yet?
Click to expand...

Wow, that poster is right, I just did a search.

"Chairman, President & CEO of Intra-cellular Therapies Inc sold 17,478 shares of ITCI on 01/02/2020 at an average price of $32.45 a share. The total sale was $567,161."
 




Wow.
Ok tin-foil hat crowd...

Ever hear of programmed trading?

The REST of the story is the Gen. Counsel and CFO sold shares the same day. The first day the market was open in 2020. Sounds like a program trade to me.

And, she reduced her overall position by, wait for it, a whopping 1.4%!!

You’re right. ITCI is dooooomed!!!!

Given the posts on here yakin’ about top tier talent and low balling pay and 401k screw jobs is it any wonder the company is hiring known quantities?

comical
 




anonymous said:
Wow.
Ok tin-foil hat crowd...

Ever hear of programmed trading?

The REST of the story is the Gen. Counsel and CFO sold shares the same day. The first day the market was open in 2020. Sounds like a program trade to me.

And, she reduced her overall position by, wait for it, a whopping 1.4%!!

You’re right. ITCI is dooooomed!!!!

Given the posts on here yakin’ about top tier talent and low balling pay and 401k screw jobs is it any wonder the company is hiring known quantities?

comical
Click to expand...

Half a mil is less than 2% of total holdings? Makes me feel much better if true but where are you getting the info?
 
















anonymous said:
Wow.
Ok tin-foil hat crowd...

Ever hear of programmed trading?

The REST of the story is the Gen. Counsel and CFO sold shares the same day. The first day the market was open in 2020. Sounds like a program trade to me.

And, she reduced her overall position by, wait for it, a whopping 1.4%!!

You’re right. ITCI is dooooomed!!!!

Given the posts on here yakin’ about top tier talent and low balling pay and 401k screw jobs is it any wonder the company is hiring known quantities?

comical
Click to expand...

thanks for clearing that up. You seem like a douche canoe, but at least you make sense.
 




anonymous said:
Are you Fuc*^ng serious??
You think you deserve the same stake in the company as the founder and CEO?

Geesus. If you’re in the candidate pool then maybe this company actually is doomed.
Click to expand...
No one thinks reps should get the same amount of shares as the CEO you bag of dicks.
But what has been offered is truly lacking. Those shares are already worth 25% less than when “offered”. That equity is laughable and does not provide any skin in the game.
 












anonymous said:
I pulled out of the 2nd round interview myself. After everything I read on cafe pharma and just selling another me too Schizophrenia drug, it just didnt make sense for me to leave a company that I love with no issues. I just didnt feel right about the opportunity. Good luck to those who are hired!
Click to expand...
You pulled out because of Cafe Pharma. Wow. Do you not realize how many lying trolls and competitors are here???? In all honesty, I hope you are not serious. Well actually I hope you are my competition for round 2
 








anonymous said:
Im concerned about the lack of Psychiatry experience and Schizophrenia experience with upper management and employees throughout the company. If you do not understand the industry and marketplace you will never be successful with this drug. I sure hope that you have hired Specialty Psychiatry reps with Schizophrenia marketplace experience to sell your new drug!
Click to expand...

I have a lot of Psych experience- sold Zyprexa in the good ole days- and I can tell you that selling in Psychiatry is about as close to primary care as it gets. ANYONE can do it. Not that hard- easy to see- managed care driven.

You want to be successful with this drug- have solid relationships and get them to write it in bipolar with insurance that will pay for it. Otherwise you are about 4th line for medicaid to pay for it.
 




anonymous said:
I have a lot of Psych experience- sold Zyprexa in the good ole days- and I can tell you that selling in Psychiatry is about as close to primary care as it gets. ANYONE can do it. Not that hard- easy to see- managed care driven.

You want to be successful with this drug- have solid relationships and get them to write it in bipolar with insurance that will pay for it. Otherwise you are about 4th line for medicaid to pay for it.
Click to expand...
Maybe I’m missing something but usually insurance doesn’t want to cover on label let alone an off label use of a new medication.
 








Top Bottom
Back
Quote